CNS Drugs

, Volume 28, Issue 10, pp 887–920 | Cite as

QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review

Review Article

Abstract

We comprehensively reviewed published literature to determine whether it supported the link between corrected QT (QTc) interval prolongation and torsade de pointes (TdP) for the 11 second-generation antipsychotics and seven second-generation antidepressants commonly implicated in these complications. Using PubMed and EMBASE, we identified four thorough QT studies (one each for iloperidone, ziprasidone, citalopram, and escitalopram), 40 studies specifically designed to assess QTc interval prolongation or TdP, 58 publications based on data from efficacy and safety trials, 18 toxicology studies, and 102 case reports. Thorough QT studies, QTc prolongation-specific studies, and studies based on efficacy and safety trials did not link drug-associated QTc interval prolongation with TdP. They only showed that the drugs reviewed caused varying degrees of QTc interval prolongation, and even that information was not clear and consistent enough to stratify individual drugs for this risk. The few toxicology studies provided valuable information but their findings are pertinent only to situations of drug overdose. Case reports were most informative about the drug–QTc interval prolongation–TdP link. At least one additional well established risk factor for QTc prolongation was present in 92.2 % of case reports. Of the 28 cases of TdP, six (21.4 %) experienced it with QTc interval <500 ms; 75 % of TdP cases occurred at therapeutic doses. There is little evidence that drug-associated QTc interval prolongation by itself is sufficient to predict TdP. Future research needs to improve its precision and broaden its scope to better understand the factors that facilitate or attenuate progression of drug-associated QTc interval prolongation to TdP.

Supplementary material

40263_2014_196_MOESM1_ESM.docx (84 kb)
Supplementary material 1 (DOCX 83 kb)

References

  1. 1.
    Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. 2003;5:205–15.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging. 2009;26:997–1012.PubMedGoogle Scholar
  3. 3.
    Hasnain M, Vieweg WV, Breden Crous EL, Hancox JC. Methadone and torsade de pointes: how can we better understand the association? Am J Med. 2013;126:757–8.PubMedGoogle Scholar
  4. 4.
    Hasnain M, Vieweg WV, Howland RH, Kogut C, Breden Crouse EL, Koneru JN, et al. Quetiapine and the need for a thorough QT/QTc study. J Clin Psychopharmacol. 2014;34:3–6.PubMedGoogle Scholar
  5. 5.
    Vieweg WV, Hasnain M, Howland RH, Hettema JM, Kogut C, Wood MA, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med. 2012;125:859–68.PubMedGoogle Scholar
  6. 6.
    Vieweg WV, Hasnain M, Hancox JC, Baranchuk A, Digby GC, Kogut C, et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Psychopharmacology (Berl). 2013;228:515–24.Google Scholar
  7. 7.
    Hasnain M, Vieweg WV, Howland R.H., Kogut C, Crouse E.L.B., Koneru JN, et al. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports. Ther Adv Psychopharmacol. 2014;4(3):130-8.Google Scholar
  8. 8.
    FDA. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. http://www.fda.gov/drugs/drugsafety/ucm297391.htm. Accessed 29 July 2014.
  9. 9.
    AstraZeneca. Quetiapine (Seroquel) Prescribing Information. http://www1.astrazeneca-us.com/pi/Seroquel.pdf. Accessed 29 July 2014.
  10. 10.
    Arizona University-Based Center for Education and Research on Therapeutics (AZCERT). CredibleMeds—A Trusted Partner Providing Reliable Information on Medicines. http://www.crediblemeds.org/everyone/. Accessed 29 July 2014.
  11. 11.
    International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. The clinical evaluation of Qt/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf. Accessed 29 July 2014.
  12. 12.
    E14 Implementation Working Group. ICH E14 Guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions & Answers (R2). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_QAs_R2_Step4.pdf. Accessed 29 July 2014.
  13. 13.
    Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17:587–92.PubMedGoogle Scholar
  14. 14.
    Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis. 2001;43:1–45.PubMedGoogle Scholar
  15. 15.
    Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2003;45:415–27.PubMedGoogle Scholar
  16. 16.
    Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol. 2001;21:8–13.PubMedGoogle Scholar
  17. 17.
    Isbister GK, Balit CR, Macleod D, Duffull SB. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol. 2010;30:391–5.PubMedGoogle Scholar
  18. 18.
    Joy JP, Coulter CV, Duffull SB, Isbister GK. Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses. Clin Pharmacol Ther. 2011;90:243–5.PubMedGoogle Scholar
  19. 19.
    Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol. 1999;14:209–18.PubMedGoogle Scholar
  20. 20.
    Stevenson RJ. Amisulpride overdose: suggested management of prolonged QTc. Emerg Med J. 2010;27:565.PubMedGoogle Scholar
  21. 21.
    Chung AK, Chua SE. Torsade de pointes associated with low-dose amisulpride: a case report. J Psychopharmacol. 2010;24:433–5.PubMedGoogle Scholar
  22. 22.
    Isbister GK, Murray L, John S, Hackett LP, Haider T, O’Mullane P, et al. Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med J Aust. 2006;184:354–6.PubMedGoogle Scholar
  23. 23.
    Ward DI. Two cases of amisulpride overdose: a cause for prolonged QT syndrome. Emerg Med Australas. 2005;17:274–6.PubMedGoogle Scholar
  24. 24.
    O’Shea M, Sazhin V, Collins A. Ventricular ectopics during crossover of atypical antipsychotics. Aust N Z J Psychiatry. 2003;37:773–4.PubMedGoogle Scholar
  25. 25.
    Pedrosa GF, Grohmann R, Ruther E. Asymptomatic bradycardia associated with amisulpride. Pharmacopsychiatry. 2001;34:259–61.Google Scholar
  26. 26.
    Grande I, Pons A, Baeza I, Torras A, Bernardo M. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum Psychopharmacol. 2011;26:397–403.PubMedGoogle Scholar
  27. 27.
    Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry. 2000;61:441–6.PubMedGoogle Scholar
  28. 28.
    Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry. 2001;179:167–71.PubMedGoogle Scholar
  29. 29.
    Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, et al. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology (Berl). 2011;216:9–16.Google Scholar
  30. 30.
    Kramer I, Rauber-Luthy C, Kupferschmidt H, Krahenbuhl S, Ceschi A. Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. Clin Neuropharmacol. 2010;33:230–4.PubMedGoogle Scholar
  31. 31.
    Nielsen J, Emborg C, Gydesen S, Dybbro J, Aagaard J, Haderup K, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2012;32:173–8.PubMedGoogle Scholar
  32. 32.
    Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, et al. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol. 2009;24:225–32.PubMedGoogle Scholar
  33. 33.
    Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol. 2009;23:305–14.PubMedGoogle Scholar
  34. 34.
    Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66:63–72.PubMedGoogle Scholar
  35. 35.
    Muscatello MR, Pandolfo G, Mico U, Lamberti CE, Abenavoli E, Scimeca G, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34:129–33.PubMedGoogle Scholar
  36. 36.
    Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009;110:80–9.PubMedGoogle Scholar
  37. 37.
    Sharma TR, Chahil R. Dose dependent, new onset QTc prolongation in a patient with paranoid schizophrenia receiving clozapine. Asian J Psychiatr. 2011;4:221–2.PubMedGoogle Scholar
  38. 38.
    Dhillon R, Bastiampillai T, Tee K, Vanlint A. Clozapine and associated QTc prolongation. Aust N Z J Psychiatry. 2011;45:1098–9.PubMedGoogle Scholar
  39. 39.
    Tanner MA, Culling W. Clozapine associated dilated cardiomyopathy. Postgrad Med J. 2003;79:412–3.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Cohen H, Loewenthal U, Matar MA, Kotler M. Reversal of pathologic cardiac parameters after transition from clozapine to olanzapine treatment: a case report. Clin Neuropharmacol. 2001;24:106–8.PubMedGoogle Scholar
  41. 41.
    Dewan V, Roth BA. Antipsychotic-induced QTc interval prolongation. Can J Psychiatry. 2004;49:646.PubMedGoogle Scholar
  42. 42.
    Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33:3–10.PubMedGoogle Scholar
  43. 43.
    Kane JM, Lauriello J, Laska E, Di MM, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28:S29–35.PubMedGoogle Scholar
  44. 44.
    Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28:S20–8.PubMedGoogle Scholar
  45. 45.
    Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28:S12–9.PubMedGoogle Scholar
  46. 46.
    FDA PsychoPharmacological Drugs Advisory Committee. FDA Background on ZeldoxTM (ziprasidone hydrochloride capsules) Pfizer, Inc. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1b.pdf. Accessed 29 July 2014.
  47. 47.
    Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62–9.PubMedGoogle Scholar
  48. 48.
    Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al. Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. Hum Psychopharmacol. 2013;28:215–9.PubMedGoogle Scholar
  49. 49.
    Suzuki Y, Ono S, Sugai T, Fukui N, Watanabe J, Tsuneyama N, et al. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. Hum Psychopharmacol. 2011;26:440–3.PubMedGoogle Scholar
  50. 50.
    Suzuki Y, Sugai T, Ono S, Sawamura K, Fukui N, Watanabe J, et al. Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia. J Clin Psychopharmacol. 2011;31:526–8.PubMedGoogle Scholar
  51. 51.
    Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al. Changes in QT interval after switching to quetiapine in Japanese patients with schizophrenia. Hum Psychopharmacol. 2013;28:94–6.PubMedGoogle Scholar
  52. 52.
    Watanabe J, Suzuki Y, Fukui N, Ono S, Sugai T, Tsuneyama N, et al. Increased risk of antipsychotic-related QT prolongation during night time: a 24-h holter electrocardiogram recording study. J Clin Psychopharmacol. 2012;32:18–22.PubMedGoogle Scholar
  53. 53.
    Huang CL, Su KP, Hsu HB, Pariante CM. A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone. J Clin Psychiatry. 2007;68:803–5.PubMedGoogle Scholar
  54. 54.
    de Castro MJ, Fraguas D, Laita P, Moreno D, Parellada M, Pascual D, et al. QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2008;18:381–3.PubMedGoogle Scholar
  55. 55.
    Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:401–5.PubMedGoogle Scholar
  56. 56.
    Meyer-Massetti C, Vaerini S, Ratz Bravo AE, Meier CR, Guglielmo BJ. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm. 2011;33:806–14.PubMedGoogle Scholar
  57. 57.
    Ou JJ, Xu Y, Chen HH, Fan X, Gao K, Wang J, et al. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology (Berl). 2013;225:627–35.Google Scholar
  58. 58.
    Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:1535–8.PubMedGoogle Scholar
  59. 59.
    Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–47.PubMedGoogle Scholar
  60. 60.
    Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol. 2005;20:105–12.PubMedGoogle Scholar
  61. 61.
    Kwon JS, Mittoux A, Hwang JY, Ong A, Cai ZJ, Su TP. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study. Int Clin Psychopharmacol. 2012;27:326–35.PubMedGoogle Scholar
  62. 62.
    Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry. 2001;62:191–8.PubMedGoogle Scholar
  63. 63.
    Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer’s dementia. Int J Geriatr Psychiatry. 2001;16(Suppl 1):S62–70.PubMedGoogle Scholar
  64. 64.
    Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158:1149–51.PubMedGoogle Scholar
  65. 65.
    Lindborg SR, Beasley CM, Alaka K, Taylor CC. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res. 2003;119:113–23.PubMedGoogle Scholar
  66. 66.
    Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441–8.PubMedGoogle Scholar
  67. 67.
    Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21:389–97.PubMedGoogle Scholar
  68. 68.
    Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494–504.PubMedGoogle Scholar
  69. 69.
    Lung DD, Wu AH, Gerona RR. Cardiotoxicity in a citalopram and olanzapine overdose. J Emerg Med. 2013;45:554–8.PubMedGoogle Scholar
  70. 70.
    Ritchie B, Norris ML. QTc prolongation associated with atypical antipsychotic use in the treatment of adolescent-onset anorexia nervosa. J Can Acad Child Adolesc Psychiatry. 2009;18:60–3.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol. 2006;109:273–4.PubMedGoogle Scholar
  72. 72.
    Su KP, Lane HY, Chuang CL, Chen KP, Shen WW. Olanzapine-induced QTc prolongation in a patient with Wolff–Parkinson–White syndrome. Schizophr Res. 2004;66:191–2.PubMedGoogle Scholar
  73. 73.
    Imran N, Rampes H, Rosen S. Antipsychotic induced prolongation of QTc interval treated with magnesium. J Psychopharmacol. 2003;17:346–9.PubMedGoogle Scholar
  74. 74.
    Dineen S, Withrow K, Voronovitch L, Munshi F, Nawbary MW, Lippmann S. QTc prolongation and high-dose olanzapine. Psychosomatics. 2003;44:174–5.PubMedGoogle Scholar
  75. 75.
    Hough DW, Natarajan J, Vandebosch A, Rossenu S, Kramer M, Eerdekens M. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2011;26:25–34.PubMedGoogle Scholar
  76. 76.
    Suzuki Y, Fukui N, Watanabe J, Ono S, Sugai T, Tsuneyama N, et al. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Hum Psychopharmacol. 2012;27:39–42.PubMedGoogle Scholar
  77. 77.
    Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69:817–29.PubMedGoogle Scholar
  78. 78.
    Gopal S, Hough D, Karcher K, Nuamah I, Palumbo J, Berlin JA, et al. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials. J Clin Psychopharmacol. 2013;33:157–61.PubMedGoogle Scholar
  79. 79.
    Balit CR, Isbister GK, Hackett LP, Whyte IM. Quetiapine poisoning: a case series. Ann Emerg Med. 2003;42:751–8.PubMedGoogle Scholar
  80. 80.
    Eyer F, Pfab R, Felgenhauer N, Strubel T, Saugel B, Zilker T. Clinical and analytical features of severe suicidal quetiapine overdoses–a retrospective cohort study. Clin Toxicol (Phila). 2011;49:846–53.Google Scholar
  81. 81.
    Isbister GK, Duffull SB. Quetiapine overdose: predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal. Int Clin Psychopharmacol. 2009;24:174–80.PubMedGoogle Scholar
  82. 82.
    Devlin JW, Roberts RJ, Fong JJ, Skrobik Y, Riker RR, Hill NS, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med. 2010;38:419–27.PubMedGoogle Scholar
  83. 83.
    Aghaienia N, Brahm NC, Lussier KM, Washington NB. Probable quetiapine-mediated prolongation of the QT interval. J Pharm Pract. 2011;24:506–12.PubMedGoogle Scholar
  84. 84.
    Barker MJ, Benitez JG, Ternullo S, Juhl GA. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Vet Hum Toxicol. 2004;46:130–2.PubMedGoogle Scholar
  85. 85.
    Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol. 2001;20:215–9.PubMedGoogle Scholar
  86. 86.
    Bodmer M, Burkard T, Kummer O, Beyrau R, Krahenbuhl S, Haschke M. Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose. Ther Drug Monit. 2008;30:553–6.PubMedGoogle Scholar
  87. 87.
    Digby G, Machaalany J, Malik P, Methot M, Simpson CS, Redfearn D, et al. Multifactorial QT interval prolongation. Cardiol J. 2010;17:184–8.PubMedGoogle Scholar
  88. 88.
    Digby GC, Perez Riera AR, Barbosa BR, Simpson CS, Redfearn DP, Methot M, et al. Acquired long QT interval: a case series of multifactorial QT prolongation. Clin Cardiol. 2011;34:577–82.PubMedGoogle Scholar
  89. 89.
    Furst BA, Champion KM, Pierre JM, Wirshing DA, Wirshing WC. Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry. 2002;51:264–5.PubMedGoogle Scholar
  90. 90.
    Gajwani P, Pozuelo L, Tesar GE. QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics. 2000;41:63–5.PubMedGoogle Scholar
  91. 91.
    Gupta S, Nienhaus K, Shah SA. Quetiapine and QTc issues: a case report. J Clin Psychiatry. 2003;64:612–3.PubMedGoogle Scholar
  92. 92.
    Kurth J, Maguire G. Pediatric case report of quetiapine overdose and QTc prolongation. Ann Clin Psychiatry. 2004;16:229–31.PubMedGoogle Scholar
  93. 93.
    Nelson S, Leung JG. Torsades de pointes after administration of low-dose aripiprazole. Ann Pharmacother. 2013;47:e11.PubMedGoogle Scholar
  94. 94.
    Precourt A, Dunewicz M, Gregoire G, Williamson DR. Multiple complications and withdrawal syndrome associated with quetiapine/venlafaxine intoxication. Ann Pharmacother. 2005;39:153–6.PubMedGoogle Scholar
  95. 95.
    Strachan PM, Benoff BA. Mental status change, myoclonus, electrocardiographic changes, and acute respiratory distress syndrome induced by quetiapine overdose. Pharmacotherapy. 2006;26:578–82.PubMedGoogle Scholar
  96. 96.
    Vieweg WV, Schneider RK, Wood MA. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand. 2005;112:318–22.PubMedGoogle Scholar
  97. 97.
    Ranjbar F, Akbarzadeh F, Ahmadi NM, Abbasnejhad M. Risperidone and corrected QT-interval prolongation in surface electrocardiogram. Pak J Biol Sci. 2012;15:496–500.PubMedGoogle Scholar
  98. 98.
    Yerrabolu M, Prabhudesai S, Tawam M, Winter L, Kamalesh M. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis. 2000;2:10–2.PubMedGoogle Scholar
  99. 99.
    Chiu CC, Chang WH, Huang MC, Chiu YW, Lane HY. Regular-dose risperidone on QTc intervals. J Clin Psychopharmacol. 2005;25:391–3.PubMedGoogle Scholar
  100. 100.
    Llerena A, Berecz R, Dorado P, de la Rubia A. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol. 2004;18:189–93.PubMedGoogle Scholar
  101. 101.
    Germano E, Italiano D, Lamberti M, Guerriero L, Privitera C, D’Amico G, et al. ECG parameters in children and adolescents treated with aripiprazole and risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2014;51:23–7.PubMedGoogle Scholar
  102. 102.
    Nahshoni E, Spitzer S, Berant M, Shoval G, Zalsman G, Weizman A. QT interval and dispersion in very young children treated with antipsychotic drugs: a retrospective chart review. J Child Adolesc Psychopharmacol. 2007;17:187–94.PubMedGoogle Scholar
  103. 103.
    Page CB, Calver LA, Isbister GK. Risperidone overdose causes extrapyramidal effects but not cardiac toxicity. J Clin Psychopharmacol. 2010;30:387–90.PubMedGoogle Scholar
  104. 104.
    Margari L, Matera E, Craig F, Petruzzelli MG, Palmieri VO, Pastore A, et al. Tolerability and safety profile of risperidone in a sample of children and adolescents. Int Clin Psychopharmacol. 2013;28:177–83.PubMedGoogle Scholar
  105. 105.
    Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol. 2010;30:518–25.PubMedGoogle Scholar
  106. 106.
    Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72:194–204.PubMedGoogle Scholar
  107. 107.
    Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21:49–56.PubMedGoogle Scholar
  108. 108.
    Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry. 2007;68:29–36.PubMedGoogle Scholar
  109. 109.
    Lazarczyk MJ, Bhuiyan ZA, Perrin N, Giannakopoulos P. Selective acquired long QT syndrome (saLQTS) upon risperidone treatment. BMC Psychiatry. 2012;12:220.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Rajabi F, Hajsheikholeslami F, Beyraghi N. Sudden cardiac death after treatment with low dose risperidone in combination with cotrimoxazole. Asian J Psychiatr. 2011;4:218–20.PubMedGoogle Scholar
  111. 111.
    Pollak PT, Verjee ZH, Lyon AW. Risperidone-induced QT prolongation following overdose correlates with serum drug concentration and resolves rapidly with no evidence of altered pharmacokinetics. J Clin Pharmacol. 2011;51:1112–5.PubMedGoogle Scholar
  112. 112.
    Blaschke D, Parwani AS, Huemer M, Rolf S, Boldt LH, Dietz R, et al. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry. 2007;40:294–5.PubMedGoogle Scholar
  113. 113.
    Ravina T, Ravina P, Gutierrez J. Acquired long QT syndrome: risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. I. Int J Cardiol. 2007;116:416–20.PubMedGoogle Scholar
  114. 114.
    Tei Y, Morita T, Inoue S, Miyata H. Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. Psychosomatics. 2004;45:450–1.PubMedGoogle Scholar
  115. 115.
    Nandagopal JJ, Craig JM, Lippmann S. QTc prolongation: possible association with risperidone and/or haloperidol. Psychosomatics. 2003;44:521.PubMedGoogle Scholar
  116. 116.
    Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother. 1997;31:867–70.PubMedGoogle Scholar
  117. 117.
    Brown K, Levy H, Brenner C, Leffler S, Hamburg EL. Overdose of risperidone. Ann Emerg Med. 1993;22:1908–10.PubMedGoogle Scholar
  118. 118.
    Posey DJ, Walsh KH, Wilson GA, McDougle CJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol. 1999;9:273–6.PubMedGoogle Scholar
  119. 119.
    Atmaca M, Yavuzkir M, Mermi O, Topuz M, Kanmaz E, Tezcan E. Effect of sertindole on QTc interval in patients with schizophrenia. Neurosci Lett. 2008;442:1–3.PubMedGoogle Scholar
  120. 120.
    Nielsen J, Andersen MP, Graff C, Kanters JK, Hardahl T, Dybbro J, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand. 2010;121:385–8.PubMedGoogle Scholar
  121. 121.
    Pezawas L, Quiner S, Moertl D, Tauscher J, Barnas C, Kufferle B, et al. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. Int Clin Psychopharmacol. 2000;15:207–14.PubMedGoogle Scholar
  122. 122.
    Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry. 2005;44:73–9.PubMedGoogle Scholar
  123. 123.
    Emul M, Dalkiran M, Coskun O, Yavuz R, Tosun M, Duran A, et al. P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration. Pharmacol Res. 2009;60:369–72.PubMedGoogle Scholar
  124. 124.
    Levy WO, Robichaux-Keene NR, Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract. 2004;10:227–32.PubMedGoogle Scholar
  125. 125.
    Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O’Gorman C, Harrigan RH. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther. 2010;32:472–91.PubMedGoogle Scholar
  126. 126.
    Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano R, O’Gorman C, Harrigan RH. Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with Schizophrenia or schizoaffective disorder. Pharmacotherapy. 2010;30:127–35.PubMedGoogle Scholar
  127. 127.
    Klein-Schwartz W, Lofton AL, Benson BE, Spiller HA, Crouch BI. Prospective observational multi-poison center study of ziprasidone exposures. Clin Toxicol (Phila). 2007;45:782–6.Google Scholar
  128. 128.
    Biederman J, Mick E, Spencer T, Dougherty M, Aleardi M, Wozniak J. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord. 2007;9:888–94.PubMedGoogle Scholar
  129. 129.
    Correll CU, Lops JD, Figen V, Malhotra AK, Kane JM, Manu P. QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry. 2011;72:854–60.PubMedPubMedCentralGoogle Scholar
  130. 130.
    Delbello MP, Versavel M, Ice K, Keller D, Miceli J. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol. 2008;18:491–9.PubMedGoogle Scholar
  131. 131.
    Findling RL, Cavus I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol. 2013;23:531–44.PubMedGoogle Scholar
  132. 132.
    Findling RL, Cavus I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2013;23:545–57.PubMedGoogle Scholar
  133. 133.
    Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol. 2007;17:779–90.PubMedGoogle Scholar
  134. 134.
    Sallee FR, Miceli JJ, Tensfeldt T, Robarge L, Wilner K, Patel NC. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:720–8.PubMedGoogle Scholar
  135. 135.
    Centorrino F, MacLean E, Salvatore P, Kidwell JE, Fogarty KV, Berry JM, et al. Ziprasidone: first year experience in a hospital setting. J Psychiatr Pract. 2004;10:361–7.PubMedGoogle Scholar
  136. 136.
    Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. 2013;33:485–90.PubMedGoogle Scholar
  137. 137.
    Kudla D, Lambert M, Domin S, Kasper S, Naber D. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry. 2007;22:195–202.PubMedGoogle Scholar
  138. 138.
    Mencacci C. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial. Pharmacopsychiatry. 2012;45:236–40.PubMedGoogle Scholar
  139. 139.
    Preval H, Klotz SG, Southard R, Francis A. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry. 2005;27:140–4.PubMedGoogle Scholar
  140. 140.
    Zhao T, Park TW, Yang JC, Huang GB, Kim MG, Lee KH, et al. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. Int Clin Psychopharmacol. 2012;27:184–90.PubMedGoogle Scholar
  141. 141.
    Greco KE, Tune LE, Brown FW, Van Horn WA. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. J Clin Psychiatry. 2005;66:928–9.PubMedGoogle Scholar
  142. 142.
    Rais AR, Williams K, Rais T, Singh T, Tamburrino M. Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. Psychiatry (Edgmont). 2010;7:17–24.Google Scholar
  143. 143.
    Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217–21.PubMedGoogle Scholar
  144. 144.
    Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132:101–7.PubMedGoogle Scholar
  145. 145.
    Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2006;21:21–8.PubMedGoogle Scholar
  146. 146.
    Camm AJ, Karayal ON, Meltzer H, Kolluri S, O’Gorman C, Miceli J, et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs. 2012;26:351–65.PubMedGoogle Scholar
  147. 147.
    Berling I, Isbister GK, Calver L, Clunas S. Digital Holter measurement of QT prolongation in ziprasidone overdose. Clin Toxicol (Phila). 2011;49:694–6.Google Scholar
  148. 148.
    Witsil JC, Zell-Kanter M, Mycyk MB. Single-dose ziprasidone associated with QT interval prolongation. Am J Emerg Med. 2012;30:837.e1–2.Google Scholar
  149. 149.
    Alipour A, Cruz R, Lott RS. Torsade de pointes after ziprasidone overdose with coingestants. J Clin Psychopharmacol. 2010;30:76–7.PubMedGoogle Scholar
  150. 150.
    Oldham MA, Catalano G, Catalano MC, Ross MM. QTc prolongation associated with ziprasidone overdose. CNS Spectr. 2008;13:E1.PubMedGoogle Scholar
  151. 151.
    Eker SS, Sarandol A, Akkaya C, Sivrioglu EY, Kirli S. The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases. J Psychopharmacol. 2009;23:993–6.PubMedGoogle Scholar
  152. 152.
    Bentley ML, Biscardi FH, Butcher C, Levitov A. Inadvertent administration of intravenous ziprasidone leading to bradycardia and QT interval prolongation. Ann Pharmacother. 2008;42:902–3.PubMedGoogle Scholar
  153. 153.
    Manini AF, Raspberry D, Hoffman RS, Nelson LS. QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine. J Med Toxicol. 2007;3:178–81.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47:264–8.PubMedGoogle Scholar
  155. 155.
    Simpson BR, Albanese RP Jr. Ziprasidone and hypokalemia: a case of 2 predisposing factors for QTc prolongation without development of torsades de pointes. Prim Care Companion J Clin Psychiatry. 2005;7:134–6.PubMedPubMedCentralGoogle Scholar
  156. 156.
    Jaffe R, Leavitt R, Wind T. QTc prolongation in multiple drug overdose. J Clin Psychopharmacol. 2004;24:348–50.PubMedGoogle Scholar
  157. 157.
    Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol. 2003;41:101–4.PubMedGoogle Scholar
  158. 158.
    Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.PubMedPubMedCentralGoogle Scholar
  159. 159.
    Dubnov-Raz G, Juurlink DN, Fogelman R, Merlob P, Ito S, Koren G, et al. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics. 2008;122:e710–5.PubMedGoogle Scholar
  160. 160.
    Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G. Symptoms and signs of severe citalopram overdose. Lancet. 1997;349:1602.PubMedGoogle Scholar
  161. 161.
    Jimmink A, Caminada K, Hunfeld NG, Touw DJ. Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monit. 2008;30:365–71.PubMedGoogle Scholar
  162. 162.
    Hayes BD, Klein-Schwartz W, Clark RF, Muller AA, Miloradovich JE. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med. 2010;39:44–8.PubMedGoogle Scholar
  163. 163.
    Yilmaz Z, Ceschi A, Rauber-Luthy C, Sauer O, Stedtler U, Prasa D, et al. Escitalopram causes fewer seizures in human overdose than citalopram. Clin Toxicol (Phila). 2010;48:207–12.Google Scholar
  164. 164.
    Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277–85.PubMedGoogle Scholar
  165. 165.
    Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol. 2004;42:67–71.PubMedGoogle Scholar
  166. 166.
    Waring WS, Graham A, Gray J, Wilson AD, Howell C, Bateman DN. Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol. 2010;70:881–5.PubMedPubMedCentralGoogle Scholar
  167. 167.
    Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol. 1999;19:407–15.PubMedGoogle Scholar
  168. 168.
    Agosti S, Casalino L, Bertero G, Burrone A, Brunelli C, Morelloni S. Citalopram and levosulpiride: a dangerous drug combination for QT prolongation. Am J Emerg Med. 2013;31:1624.e1–2.Google Scholar
  169. 169.
    Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K. Prolonged QTc interval and torsades de pointes induced by citalopram. Tex Heart Inst J. 2012;39:68–70.PubMedPubMedCentralGoogle Scholar
  170. 170.
    Unterecker S, Warrings B, Deckert J, Pfuhlmann B. Correlation of QTc interval prolongation and serum level of citalopram after intoxication–a case report. Pharmacopsychiatry. 2012;45:30–4.PubMedGoogle Scholar
  171. 171.
    Liotier J, Coudore F. Drug monitoring of a case of citalopram overdosage. Drug Chem Toxicol. 2011;34:420–3.PubMedGoogle Scholar
  172. 172.
    Fayssoil A, Issi J, Guerbaa M, Raynaud JC, Heroguelle V. Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris). 2011;60:165–8.Google Scholar
  173. 173.
    de Gregorio C, Morabito G, Cerrito M, Dattilo G, Oreto G. Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. Int J Cardiol. 2011;148:226–8.PubMedGoogle Scholar
  174. 174.
    Venkatraman N, O’Neil D, Hall AP. Life-threatening overdose with lamotrigine, citalopram, and chlorpheniramine. J Postgrad Med. 2008;54:316–7.PubMedGoogle Scholar
  175. 175.
    Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol. 2008;4:101–5.PubMedPubMedCentralGoogle Scholar
  176. 176.
    Kanjanauthai S, Kanluen T, Chareonthaitawee P. Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol. 2008;131:e33–4.PubMedGoogle Scholar
  177. 177.
    Engebretsen KM, Harris CR, Wood JE. Cardiotoxicity and late onset seizures with citalopram overdose. J Emerg Med. 2003;25:163–6.PubMedGoogle Scholar
  178. 178.
    Catalano G, Catalano MC, Epstein MA, Tsambiras PE. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol. 2001;24:158–62.PubMedGoogle Scholar
  179. 179.
    Bucklin MH, Gorodetsky RM, Wiegand TJ. Prolonged lipemia and pancreatitis due to extended infusion of lipid emulsion in bupropion overdose. Clin Toxicol (Phila). 2013;51:896–8.Google Scholar
  180. 180.
    Altin T, Ozcan O, Turhan S, Ozdemir AO, Akyurek O, Karaoguz R, et al. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol. 2007;23:907–8.PubMedPubMedCentralGoogle Scholar
  181. 181.
    van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. Br J Clin Pharmacol. 2012;73:402–10.PubMedPubMedCentralGoogle Scholar
  182. 182.
    Hanash JA, Hansen BH, Hansen JF, Nielsen OW, Rasmussen A, Birket-Smith M. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. J Cardiovasc Pharmacol. 2012;60:397–405.PubMedGoogle Scholar
  183. 183.
    Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23:1391–400.PubMedGoogle Scholar
  184. 184.
    Mohammed R, Norton J, Geraci SA, Newman DB, Koch CA. Prolonged QTc interval due to escitalopram overdose. J Miss State Med Assoc. 2010;51:350–3.PubMedGoogle Scholar
  185. 185.
    Baranchuk A, Simpson CS, Methot M, Gibson K, Strum D. Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. Can J Cardiol. 2008;24:e38–40.PubMedPubMedCentralGoogle Scholar
  186. 186.
    Scharko AM, Schumacher J. Prolonged QTc interval in a 14-year-old girl with escitalopram overdose. J Child Adolesc Psychopharmacol. 2008;18:297–8.PubMedGoogle Scholar
  187. 187.
    Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review. Gen Hosp Psychiatry. 2012;34:210–5.Google Scholar
  188. 188.
    Beyenburg S, Schonegger K. Severe bradycardia in a stroke patient caused by a single low dose of escitalopram. Eur Neurol. 2007;57:50–1.PubMedGoogle Scholar
  189. 189.
    Schreffler SM, Marraffa JM, Stork CM, Mackey J. Sodium channel blockade with QRS widening after an escitalopram overdose. Pediatr Emerg Care. 2013;29:998–1001.PubMedGoogle Scholar
  190. 190.
    Zhao Q, Wojcik MA, Parier JL, Pesco-Koplowitz L. Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers. Pharmacotherapy. 2001;21:149–57.PubMedGoogle Scholar
  191. 191.
    Baker B, Dorian P, Sandor P, Shapiro C, Schell C, Mitchell J, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17:15–21.PubMedGoogle Scholar
  192. 192.
    Adetunji B, Basil B, Mathews M, Osinowo T. Should the Physician’s Desk Reference contraindicate the use of chlorpromazine-fluoxetine combination? A case report. J Clin Psychopharmacol. 2006;26:438.PubMedGoogle Scholar
  193. 193.
    Wilting I, Smals OM, Holwerda NJ, Meyboom RH, de Bruin ML, Egberts TC. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry. 2006;163:325.PubMedGoogle Scholar
  194. 194.
    Dubnov G, Fogelman R, Merlob P. Prolonged QT interval in an infant of a fluoxetine treated mother. Arch Dis Child. 2005;90:972–3.PubMedPubMedCentralGoogle Scholar
  195. 195.
    Suchard JR. Fluoxetine overdose-induced seizure. West J Emerg Med. 2008;9:154–6.PubMedPubMedCentralGoogle Scholar
  196. 196.
    Varriale P. Fluoxetine (Prozac) as a cause of QT prolongation. Arch Intern Med. 2001;161:612.PubMedGoogle Scholar
  197. 197.
    Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005;39:543–6.PubMedGoogle Scholar
  198. 198.
    Appleby M, Mbewu A, Clarke B. Fluoxetine and ventricular torsade–is there a link? Int J Cardiol. 1995;49:178–80.PubMedGoogle Scholar
  199. 199.
    Michalets EL, Smith LK, Van Tassel ED. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother. 1998;32:761–5.PubMedGoogle Scholar
  200. 200.
    Graudins A, Vossler C, Wang R. Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy. Am J Emerg Med. 1997;15:501–3.PubMedGoogle Scholar
  201. 201.
    Martin DE, Zussman BD, Everitt DE, Benincosa LJ, Etheredge RC, Jorkasky DK. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Psychopharmacol. 1997;17:451–9.PubMedGoogle Scholar
  202. 202.
    Kuhs H, Rudolf GA. Cardiovascular effects of paroxetine. Psychopharmacology (Berl). 1990;102:379–82.Google Scholar
  203. 203.
    Edwards JG, Goldie A, Papayanni-Papasthatis S. Effect of paroxetine on the electrocardiogram. Psychopharmacology (Berl). 1989;97:96–8.Google Scholar
  204. 204.
    Nelson JC, Lu PY, Martynov O, Yu JY, Mallinckrodt CH, Detke MJ. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry. 2006;8:212–9.PubMedPubMedCentralGoogle Scholar
  205. 205.
    Krulewicz S, Carpenter DJ, Fong R, Horrigan JP, Lipschitz A, Perera P, et al. Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:422–30.PubMedGoogle Scholar
  206. 206.
    Alderman J. Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Clin Ther. 2005;27:1050–63.PubMedGoogle Scholar
  207. 207.
    Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–9.PubMedGoogle Scholar
  208. 208.
    Wilens TE, Biederman J, March JS, Wolkow R, Fine CS, Millstein RB, et al. Absence of cardiovascular adverse effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38:573–7.PubMedGoogle Scholar
  209. 209.
    Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: a critical analysis. J Clin Psychiatry. 1990;51(Suppl B):37–9.PubMedGoogle Scholar
  210. 210.
    Patane S, Marte F, Di BG. QT interval prolongation and torsade de pointes. Int J Cardiol. 2009;131:e51–3.PubMedGoogle Scholar
  211. 211.
    de Boer RA, van Dijk TH, Holman ND, van Melle JP. QT interval prolongation after sertraline overdose: a case report. BMC Emerg Med. 2005;5:5.PubMedPubMedCentralGoogle Scholar
  212. 212.
    Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007;22:129–33.PubMedGoogle Scholar
  213. 213.
    Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry. 2006;14:796–802.PubMedGoogle Scholar
  214. 214.
    Isbister GK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol. 2009;67:572–6.PubMedPubMedCentralGoogle Scholar
  215. 215.
    Chan AN, Gunja N, Ryan CJ. A comparison of venlafaxine and SSRIs in deliberate self-poisoning. J Med Toxicol. 2010;6:116–21.PubMedPubMedCentralGoogle Scholar
  216. 216.
    Batista M, Dugernier T, Simon M, Haufroid V, Capron A, Fonseca S, et al. The spectrum of acute heart failure after venlafaxine overdose. Clin Toxicol (Phila). 2013;51:92–5.Google Scholar
  217. 217.
    Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol. 2008;4:18–20.PubMedPubMedCentralGoogle Scholar
  218. 218.
    Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F. QT interval prolongation associated with venlafaxine administration. Int J Cardiol. 2006;109:116–7.PubMedGoogle Scholar
  219. 219.
    Wang Y, Pan G, Balch A. Bias and variance evaluation of QT interval correction methods. J Biopharm Stat. 2008;18:427–50.PubMedGoogle Scholar
  220. 220.
    Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001;12:411–20.PubMedGoogle Scholar
  221. 221.
    Hingorani P, Karnad DR, Natekar M, Kothari S, Narula D, Lokhandwala Y. QTc interval and its variability in patients with schizophrenia and healthy subjects: implications for a thorough QT study. Int J Neuropsychopharmacol. 2012;15:1535–40.PubMedGoogle Scholar
  222. 222.
    Nielsen J. QTc prolongation and clozapine: fact or artefact? Aust N Z J Psychiatry. 2012;46:793–4.PubMedGoogle Scholar
  223. 223.
    Law D, Mohan T, Bastiampillai T, Dhillon R. Clozapine rechallenge following QTc prolongation. Aust N Z J Psychiatry. 2013.Google Scholar
  224. 224.
    Chung AK, Chua SE. Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25:646–66.PubMedGoogle Scholar
  225. 225.
    van Driel ML, De SA, De MJ, Christiaens T. Searching for unpublished trials in Cochrane reviews may not be worth the effort. J Clin Epidemiol. 2009;62:838–44.PubMedGoogle Scholar
  226. 226.
    Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.PubMedGoogle Scholar
  227. 227.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf. Accessed 29 July 2014.
  228. 228.
    Farkas AS, Nattel S. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Drugs. 2010;70:573–603.PubMedGoogle Scholar
  229. 229.
    Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Hattenhauer J, Mariani R, et al. Prolonged Tpeak-to-Tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol. 2011;4:441–7.PubMedPubMedCentralGoogle Scholar
  230. 230.
    Hondeghem LM. QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm. 2008;5:1210–2.PubMedGoogle Scholar
  231. 231.
    Davey P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods. 2002;48:3–9.PubMedGoogle Scholar
  232. 232.
    Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol. 2004;37 Suppl:81–90.PubMedGoogle Scholar
  233. 233.
    Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011;25:473–90.PubMedGoogle Scholar
  234. 234.
    Postema PG, De Jong JS, Van der Bilt IA, Wilde AA. Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm. 2008;5:1015–8.PubMedGoogle Scholar
  235. 235.
    Chan A, Isbister GK, Kirkpatrick CM, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM. 2007;100:609–15.PubMedGoogle Scholar
  236. 236.
    Straus SM, Kors JA, de Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362–7.PubMedGoogle Scholar
  237. 237.
    Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz JH et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf 2006; 15:361-368.Google Scholar
  238. 238.
    Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114:135–41.PubMedGoogle Scholar
  239. 239.
    Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol. 2007;40:228–34.PubMedGoogle Scholar
  240. 240.
    Carella MJ, Mantz SL, Rovner DR, Willis PW III, Gossain VV, Bouknight RR, et al. Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss. Int J Obes Relat Metab Disord. 1996;20:938–42.PubMedGoogle Scholar
  241. 241.
    Soydinc S, Davutoglu V, Akcay M. Uncomplicated metabolic syndrome is associated with prolonged electrocardiographic QTc interval and QTc dispersion. Ann Noninvasive Electrocardiol. 2006;11:313–7.PubMedGoogle Scholar
  242. 242.
    Tasolar H, Balli M, Bayramoglu A, Otlu YO, Cetin M, Altun B, et al. Effect of Smoking on Tp-e interval, Tp-e/QT and Tp-e/QTc ratios as indices of ventricular arrhythmogenesis. Heart Lung Circ. 2014.Google Scholar
  243. 243.
    Erbas O, Yilmaz M. Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats. Toxicol Ind Health. 2013.Google Scholar
  244. 244.
    Ng TM, Olsen KM, McCartan MA, Puumala SE, Speidel KM, Miller MA, et al. Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors. J Pharm Pract. 2010;23:19–24.PubMedGoogle Scholar
  245. 245.
    Mahida S, Hogarth AJ, Cowan C, Tayebjee MH, Graham LN, Pepper CB. Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. J Interv Card Electrophysiol. 2013;37:9–19.PubMedGoogle Scholar
  246. 246.
    Gouas L, Nicaud V, Berthet M, Forhan A, Tiret L, Balkau B, et al. Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. Eur J Hum Genet. 2005;13:1213–22.PubMedGoogle Scholar
  247. 247.
    Al-Zaiti SS, Fallavollita JA, Wu YW, Tomita MR, Carey MG. Electrocardiogram-based predictors of clinical outcomes: A meta-analysis of the prognostic value of ventricular repolarization. Heart Lung. 2014.Google Scholar
  248. 248.
    Nielsen J, Graff C, Hardahl T, Andersen MP, Kristoffersen J, Struijk JJ, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol. 2009;19:702–7.PubMedGoogle Scholar
  249. 249.
    Axelsson R, Aspenstrom G. Electrocardiographic changes and serum concentrations in thioridazine-treated patients. J Clin Psychiatry. 1982;43:332–5.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of PsychiatryMemorial UniversitySt John’sCanada
  2. 2.Department of Psychiatry and Department of Internal MedicineVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations